Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 19;10:2939. doi: 10.1038/s41598-020-59853-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

In vivo tumor growth and angiogenesis of Mock and VEGFR2-Fc–expressing tumors. (a,b) In vivo tumor growth of Mock and VEGFR2-Fc–expressing tumors. (a) Renca model; (b) B16F10 model. Data are means ± SEM (n = 7 in Renca model and n = 8 in B16F10 model). *p < 0.05 (unpaired t-test). Comparison of tumor volumes between Mock and VEGFR2-Fc–expressing groups was conducted for the last time point of the Mock group in (a) Day 24 and (b) Day 16. (c,d) Tumor angiogenesis of Mock and VEGFR2-Fc–expressing tumors. Representative images of CD31 staining (marker of endothelial cells; red) and DAPI (4′,6-diamidino-2-phenylindole) (marker of DNA; blue). (c) Renca model; (d) B16F10 model. Scale bars represent 100 μm. (e,f) Expression of VEGFR2-Fc (detected by anti-IgG Ab) in tumors resected at volumes of ~500 mm³. (e) Renca model; (f) B16F10 model. Three independent tumors were analyzed. (g,h) Immunoprecipitation assay for co-precipitation of VEGFR2-Fc with endogenous VEGF, FGF1, or FGF2 in Mock or VEGFR2-Fc–expressing tumor lysates. (g) Renca model; (h) B16F10 model. IB, Immunoblotting.